22:50 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: B cell lymphoma Cell and mouse studies suggest promoting PMAIP1 expression or inhibiting MCL1 could enhance the efficacy of BCL-2 inhibitors to treat diffuse large B cell lymphoma (DLBCL). In a DLBCL cell line,...
01:10 , Nov 10, 2018 |  BC Extra  |  Preclinical News

June highlights shorter CAR T culture times at SITC

In a presentation at the Society for Immunotherapy of Cancer (SITC) meeting Friday, CAR T cell pioneer Carl June highlighted preclinical data from University of Pennsylvania suggesting CAR T cell therapies could require as little...
03:10 , Nov 3, 2018 |  BioCentury  |  Politics, Policy & Law

Backing into value with Part B

The Trump Administration’s proposed revamp of Medicare Part B would cede value determinations to other countries by importing their cost-effectiveness standards on drug pricing. It could also lead to more experiments with alternative models for...
21:20 , Oct 29, 2018 |  BC Extra  |  Politics & Policy

Bach, Trusheim, Sen. Cassidy outline scheme for subscription-based purchasing

Peter Bach, Mark Trusheim and Sen. Bill Cassidy (R-La.) outlined a model for states to use as a basic reference point when implementing a subscription-based drug payment model for HCV drugs like the one proposed...
00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
03:01 , Oct 13, 2018 |  BioCentury  |  Politics, Policy & Law

COI failure fallout

Jose Baselga resigned as CMO of Memorial Sloan Kettering Cancer Center after being accused of failing to disclose conflicts of interest, upsetting a hornet’s nest on his way out the door that is causing academic...
22:15 , Oct 3, 2018 |  BC Extra  |  Company News

MSKCC President & CEO resigns from Merck's board

President and CEO of Memorial Sloan Kettering Cancer Center Craig Thompson will immediately resign from the boards of Merck & Co. Inc. (NYSE:MRK) and Charles River Laboratories International Inc. (NYSE:CRL) following revelations of financial ties...
21:43 , Sep 18, 2018 |  BC Innovations  |  Translation in Brief

Advanced drivers’ ed for cancer

A pair of studies published this month in...
22:38 , Sep 14, 2018 |  BC Extra  |  Company News

ACS’s Brawley disappointed in Baselga resignation

American Cancer Society Chief Medical and Scientific Officer Otis Brawley said he was disappointed that José Baselga resigned from Memorial Sloan Kettering Cancer Center after failing to disclose financial ties to industry. Baselga, who was...
19:32 , Sep 7, 2018 |  BC Week In Review  |  Company News

Atara partners with Moffitt Cancer Center to develop CAR T therapies

Atara Biotherapeutics Inc. (NASDAQ:ATRA) partnered with H. Lee Moffitt Cancer Center and Research Institute (Tampa, Fla.) to develop multi‑targeted CAR T immunotherapies to treat cancers with diverse cell types that often become resistant to treatment,...